Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, details RBN-2397 as a novel anticancer therapeutic. This drug in an oral, potent, selective, small molecule PARP7 inhibitor which functions to reactivate interferon signaling and antitumor immunity. The Phase I clinical trial of RBN-2397 (NCT04053673) has noted the drug has a favorable safety profile, and preliminary anti-tumor activity was observed in both the dose-escalation and dose-expansion cohorts. Most notably was the observed partial response in one patient per cohort, and the achievement of stable disease in many others regardless of tumor type. Overall, the trial supports the position of RBN-2397 as a novel anticancer drug and corroborates ongoing studies using the drug in combination with pembrolizumab (NCT05127590) and nivolumab (jRCT2031210373) respectively. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
